-

SynergenX Expands Treatment Options to Give Patients More Flexible Paths to a Better Quality of Life

HOUSTON--(BUSINESS WIRE)--SynergenX, alongside its affiliated brands Low T Center and HerKare, today announced the launch of an expanded range of treatment options designed to give patients more flexibility, more choice, and more control over their care. These new offerings will be available across all clinic locations and through select telehealth services as of April, 2026.

The expanded lineup introduces new ways to address some of the most common concerns patients face, including low libido, hair loss, low testosterone, and weight management. New options include PT-141, an FDA-approved peptide therapy that supports libido in women; Minoxidil, an FDA-approved treatment for hair restoration; and Enclomiphene Citrate, an oral therapy that helps increase testosterone levels while preserving fertility. Patients will also have access to Sildenafil ODT and Tadalafil ODT, which use FDA-approved active ingredients to support sexual performance with both short-acting and longer-duration options.

Additional offerings include oral weight management treatments such as Semaglutide ODT and GLP-1/GIP ODT therapies. Wellness-focused treatments, including Vitamin D injections and Glutathione, are also available to support overall health, recovery, and immune function.

Together, these options create more personalized starting points for patients, including non-injection and non-hormonal approaches for those who may not be ready for traditional hormone therapy, allowing more patients to feel great, look great, and live their best lives.

“Our goal is simple: to do all we can to help patients feel like themselves again,” said Wayne Wilson, Founder and Chief Executive Officer of SynergenX. “By expanding the ways patients can begin treatment, we’re making care more approachable, more personalized, and easier to fit into everyday life.”

All treatments are delivered within a provider-led model that includes comprehensive testing, individualized treatment plans, and ongoing medical oversight. Patients can choose in-clinic care or convenient at-home options, depending on their needs.

This expansion reflects SynergenX’s continued commitment to meeting patients where they are and supporting long-term health, confidence, and quality of life.

For more information or to schedule a consultation, visit SynergenX.com.

Contacts

Media Contact:
Jordan Bailey
Marketing Communications Specialist, SynergenX / Low T Center
8326391569
jbailey@synergenxhealth.com

SynergenX


Release Versions

Contacts

Media Contact:
Jordan Bailey
Marketing Communications Specialist, SynergenX / Low T Center
8326391569
jbailey@synergenxhealth.com

More News From SynergenX

SynergenX Network Clinics Launch 2026 New Year, Healthy You Campaign

HOUSTON--(BUSINESS WIRE)--SynergenX, the veteran-owned leader in provider-led, personalized hormone and wellness medicine, is launching a bold New Year 2026 campaign designed to make hormone testing, wellness care, and medical weight loss more accessible across the SynergenX network clinics, including Low T Center and HerKare. Built around the belief that better healthcare starts with access, the initiative brings together comprehensive testing, board-certified provider consultations, and inten...

SynergenX Network Clinics Expand Peptide Therapy Options with BPC-157 and CJC-1295 + Ipamorelin

HOUSTON--(BUSINESS WIRE)--SynergenX, veteran-owned leader in personalized hormone and wellness medicine, is expanding its peptide therapy program with the addition of BPC-157 and CJC-1295 + Ipamorelin, two popular new peptide therapies that allow patients to pursue natural, rejuvenating option for health optimization, alone or in addition to hormone and weight-loss therapies. Beginning October 6, 2025, patients across SynergenX, Low T Center, and HerKare locations will have access to these adva...

SynergenX Opens Testosterone Cypionate Therapy to Female Patients

HOUSTON--(BUSINESS WIRE)--SynergenX, national leader in customized hormone optimization, prescription weight loss, and medically supervised wellness, is expanding its hormone replacement therapy (HRT) services for women to include injections of testosterone cypionate. Beginning July 28, 2025, these services will be available at all locations nationwide. This expansion marks the first time that female patients can access the custom-dosed testosterone cypionate injections available to male patien...
Back to Newsroom